StockNews.AI
AIM
StockNews.AI
5 days

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

1. AIM will participate in the Webull Financial Biotech/MedTech Webinar series. 2. Presentation scheduled for August 20, 2025, at 2:40 PM ET. 3. Thomas Equels, CEO of AIM, will present key developments. 4. AIM focuses on therapeutics for cancers, immune disorders, and viral diseases. 5. Ampligen® is AIM's lead investigational drug, undergoing clinical trials.

4m saved
Insight
Article

FAQ

Why Bullish?

Participation in high-visibility webinars can enhance AIM's market visibility and attract investors. Historical instances show that biotech firms announcing significant presentations often see positive stock reactions.

How important is it?

The webinar allows AIM to showcase its therapeutic advancements, potentially leading to increased investor interest and stock price stability. The relevance stems from the strategic presentation of their lead product, Ampligen®, amidst enhancing industry visibility.

Why Short Term?

The event is upcoming and can influence immediate investor interest. Similar past presentations have led to rapid stock activity shortly after announcements.

Related Companies

AMGNMRNANVAX
OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:40 PM ET Presenter: Thomas Equels, Chief Executive Officer, President & Executive Vice ChairmanRegistration Link: Webull Webinars About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Related News